Literature DB >> 28571116

Plasma microRNA signature is associated with risk stratification in prostate cancer patients.

Abeer Al-Qatati1, Christine Akrong1, Ines Stevic1, Klaus Pantel1, Julius Awe2, Jeff Saranchuk3, Darrel Drachenberg3, Sabine Mai2, Heidi Schwarzenbach1.   

Abstract

The aim of this study was to establish a unique expression profile of circulating cell-free microRNAs (miRNAs) capable of differentiating between prostate cancer (PCa) patients with high-risk and intermediate-risk Gleason scores. MiRNA expression profiles were determined in plasma samples from 79 treatment-naïve PCa patients, 1-2 follow-up samples after radical prostatectomy (RP) from 51 out of the 79 PCa patients, and 33 healthy men, using a quantitative real-time PCR-based array containing 48 selected miRNAs. We identified 27 up- and 2 downregulated plasma miRNAs in PCa patients compared with healthy men. Most of the upregulated miRNA levels were also associated with increasing PSA levels and Gleason scores. Particularly, the levels of miR-16 (p = 0.002), miR-148a (p = 0.006) and miR-195 (p = 0.006) significantly correlated with high-risk Gleason scores, whereby miR-148a (p = 0.003) was also significantly associated with increasing PSA values. The high miRNA levels before RP remained increased in the postsurgical plasma samples. Our findings show a network of deregulated plasma miRNAs. In particular, miR-16, miR-148a and miR-195 are involved in the regulation of the PI3K/Akt signaling pathway. These miRNAs may be promising therapeutic targets for high-risk PCa stratification.
© 2017 UICC.

Entities:  

Keywords:  Gleason scores; PI3K/Akt signaling pathway; circulating cell-free microRNAs; high-risk patients; intermediate-risk patients; radical prostatectomy

Mesh:

Substances:

Year:  2017        PMID: 28571116     DOI: 10.1002/ijc.30815

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  18 in total

1.  Circulating microRNAs in plasma before and after radical prostatectomy.

Authors:  Alicia C McDonald; Jay D Raman; Jing Shen; Jason Liao; Bhavyata Pandya; Manish A Vira
Journal:  Urol Oncol       Date:  2019-08-14       Impact factor: 3.498

Review 2.  The potential of cell-free and exosomal microRNAs as biomarkers in liquid biopsy in patients with prostate cancer.

Authors:  Monyse de Nóbrega; Mariana Bisarro Dos Reis; Érica Romão Pereira; Marilesia Ferreira de Souza; Ilce Mara de Syllos Cólus
Journal:  J Cancer Res Clin Oncol       Date:  2022-08-04       Impact factor: 4.322

3.  MiR-484 suppressed proliferation, migration, invasion and induced apoptosis of gastric cancer via targeting CCL-18.

Authors:  Jin Liu; Shi Meng Li
Journal:  Int J Exp Pathol       Date:  2020-09-28       Impact factor: 1.925

4.  MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia.

Authors:  Irena Abramovic; Borna Vrhovec; Lucija Skara; Alen Vrtaric; Nora Nikolac Gabaj; Tomislav Kulis; Goran Stimac; Dejan Ljiljak; Boris Ruzic; Zeljko Kastelan; Bozo Kruslin; Floriana Bulic-Jakus; Monika Ulamec; Ana Katusic-Bojanac; Nino Sincic
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

Review 5.  Significance of microRNAs in Androgen Signaling and Prostate Cancer Progression.

Authors:  Ken-Ichi Takayama; Aya Misawa; Satoshi Inoue
Journal:  Cancers (Basel)       Date:  2017-08-07       Impact factor: 6.639

Review 6.  Emerging biomarkers in the diagnosis of prostate cancer.

Authors:  Xavier Filella; Esther Fernández-Galan; Rosa Fernández Bonifacio; Laura Foj
Journal:  Pharmgenomics Pers Med       Date:  2018-05-16

Review 7.  MicroRNAs as Guardians of the Prostate: Those Who Stand before Cancer. What Do We Really Know about the Role of microRNAs in Prostate Biology?

Authors:  Thomas Andl; Kavya Ganapathy; Alexia Bossan; Ratna Chakrabarti
Journal:  Int J Mol Sci       Date:  2020-07-07       Impact factor: 5.923

8.  Quantification of microRNA levels in plasma - Impact of preanalytical and analytical conditions.

Authors:  Helle Glud Binderup; Jonna Skov Madsen; Niels Henrik Helweg Heegaard; Kim Houlind; Rikke Fredslund Andersen; Claus Lohman Brasen
Journal:  PLoS One       Date:  2018-07-19       Impact factor: 3.240

9.  Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling.

Authors:  Yubo Tang; Jincheng Pan; Shuai Huang; Xinsheng Peng; Xuenong Zou; Yongxiang Luo; Dong Ren; Xin Zhang; Ronggang Li; Peiheng He; Qingde Wa
Journal:  J Exp Clin Cancer Res       Date:  2018-07-18

10.  Profiling of Circulating microRNAs in Prostate Cancer Reveals Diagnostic Biomarker Potential.

Authors:  Jacob Fredsøe; Anne K I Rasmussen; Peter Mouritzen; Marianne T Bjerre; Peter Østergren; Mikkel Fode; Michael Borre; Karina D Sørensen
Journal:  Diagnostics (Basel)       Date:  2020-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.